Ilya Pharma participates at SIN UK-Northern Europe Panel on "Galvanising AMR Financing" Nov 27, British Ambassadors Residence
Anti-microbial resistance (AMR) is an escalating global health and socio-economic development threat. In September this year, the UN General (UNGA) convened a High-Level-Meeting (HLM) on AMR – which was the most significant high-level political meeting on the topic since 2016.
UK’s Government is driving global action on AMR by closely collaborating with international partners. Moving forward, together with the UK’s Department for Health and Social Care, published of UKs 5-year action plan for antimicrobial resistance 2024-2029 and the UK Special Envoy on AMR Professor Dame Sally Davies. Representatives from the government and AMR actors from the UK, the Nordics, Baltics, and the Netherlands are invited to discuss the opportunities to join forces and to explore how to tackle AMR together for a lasting impact beyond the HLM 2024.
From Ilya Pharma, CEO Evelina Vågesjö is attending and we are happy to be invited to share, collaborate and contribute to the solution - with the dual action of the ILP-drug candidates, all being developed as immunotherapies and having inherent potent antimicrobial effects in clinical doses, especially against multi drug resistant pathogens.